Edap Tms Competitors

Natus Medical (NASDAQ:NTUS) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares Natus Medical and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Natus Medical and Edap Tms, as provided by MarketBeat.com.

Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than Natus Medical.

Volatility and Risk

Natus Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and Edap Tms' net margins, return on equity and return on assets.

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AxoGen (NASDAQ:AXGN) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares AxoGen and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AxoGen and Edap Tms, as provided by MarketBeat.com.

AxoGen currently has a consensus target price of $23.75, indicating a potential upside of 25.99%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than AxoGen.

Volatility and Risk

AxoGen has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Profitability

This table compares AxoGen and Edap Tms' net margins, return on equity and return on assets.

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Edap Tms beats AxoGen on 8 of the 13 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

76.7% of TransMedics Group shares are owned by institutional investors. 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares TransMedics Group and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TransMedics Group and Edap Tms' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for TransMedics Group and Edap Tms, as provided by MarketBeat.

TransMedics Group presently has a consensus target price of $44.20, indicating a potential upside of 63.52%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Edap Tms.

Summary

Edap Tms beats TransMedics Group on 7 of the 13 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

83.0% of ViewRay shares are owned by institutional investors. 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

ViewRay has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares ViewRay and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has lower revenue, but higher earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ViewRay and Edap Tms' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for ViewRay and Edap Tms, as provided by MarketBeat.

ViewRay presently has a consensus target price of $4.50, indicating a potential upside of 2.74%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than ViewRay.

Summary

Edap Tms beats ViewRay on 8 of the 14 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and Edap Tms (NASDAQ:EDAP) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

87.8% of Cutera shares are owned by institutional investors. 2.3% of Cutera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Cutera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cutera and Edap Tms' revenue, earnings per share (EPS) and valuation.

Edap Tms has lower revenue, but higher earnings than Cutera. Cutera is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cutera and Edap Tms' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Cutera and Edap Tms, as provided by MarketBeat.

Cutera presently has a consensus target price of $30.6667, indicating a potential upside of 1.65%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Edap Tms' stronger consensus rating and higher probable upside, analysts plainly believe Edap Tms is more favorable than Cutera.

Summary

Edap Tms beats Cutera on 9 of the 13 factors compared between the two stocks.

Zynex (NASDAQ:ZYXI) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Zynex and Edap Tms, as provided by MarketBeat.

Zynex presently has a consensus target price of $21.6250, indicating a potential upside of 40.79%. Edap Tms has a consensus target price of $12.50, indicating a potential upside of 37.67%. Given Zynex's higher probable upside, analysts plainly believe Zynex is more favorable than Edap Tms.

Risk & Volatility

Zynex has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Zynex and Edap Tms' revenue, earnings per share (EPS) and valuation.

Zynex has higher earnings, but lower revenue than Edap Tms. Zynex is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

29.6% of Zynex shares are owned by institutional investors. 50.5% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Zynex and Edap Tms' net margins, return on equity and return on assets.

Summary

Zynex beats Edap Tms on 10 of the 14 factors compared between the two stocks.